[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,089,154
  • Shares Outstanding, K 356,511
  • Annual Sales, $ 9,680 K
  • Annual Income, $ -250,640 K
  • EBIT $ -90 M
  • EBITDA $ -85 M
  • 60-Month Beta 1.06
  • Price/Sales 215.73
  • Price/Cash Flow N/A
  • Price/Book 103.25

Options Overview Details

View History
  • Implied Volatility 93.79% (+4.54%)
  • Historical Volatility 78.63%
  • IV Percentile 33%
  • IV Rank 18.03%
  • IV High 256.48% on 08/14/25
  • IV Low 58.01% on 05/15/26
  • Expected Move (DTE 18) 0.81 (13.48%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,356
  • Volume Avg (30-Day) 3,848
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 95,823
  • Open Int (30-Day) 74,504
  • Expected Range 5.18 to 6.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 2
  • High Estimate $-0.01
  • Low Estimate $-0.02
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) +90.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.51 +67.52%
on 06/08/26
6.04 -2.65%
on 06/29/26
+1.54 (+35.48%)
since 05/29/26
3-Month
3.22 +82.61%
on 03/30/26
6.04 -2.65%
on 06/29/26
+2.21 (+60.22%)
since 03/27/26
52-Week
1.39 +321.51%
on 07/01/25
6.04 -2.65%
on 06/29/26
+4.46 (+314.08%)
since 06/27/25

Most Recent Stories

More News
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

GERMANTOWN, Md. and FORT WORTH, Texas , June 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative...

PGEN : 5.90 (+0.68%)
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

GERMANTOWN, Md. , May 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 5.90 (+0.68%)
Precigen Q1 Earnings Call Highlights

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.On...

PGEN : 5.90 (+0.68%)
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

GERMANTOWN, Md. , March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 5.90 (+0.68%)
Precigen Reports Full Year 2025 Financial Results and Business Updates

GERMANTOWN, Md. , March 25, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 5.90 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional...

See More

Key Turning Points

3rd Resistance Point 6.51
2nd Resistance Point 6.23
1st Resistance Point 6.05
Last Price 5.90
1st Support Level 5.58
2nd Support Level 5.30
3rd Support Level 5.11

See More

52-Week High 6.04
Last Price 5.90
Fibonacci 61.8% 4.27
Fibonacci 50% 3.72
Fibonacci 38.2% 3.17
52-Week Low 1.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.